Scienmag
JANUARY 5, 2021
– A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients. Credit: Chris Adam/Purdue University WEST LAFAYETTE, Ind. The work is supported by the National Institutes of Health and is published in Biophysical Journal.
Scienmag
OCTOBER 21, 2020
Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
FEBRUARY 1, 2021
Credit: UVA Health Scientists have identified a group of drugs that may help stop a leading cause of vision loss after making an unexpected discovery that overturns a fundamental belief about DNA. The drugs, known as Nucleoside Reverse Transcriptase Inhibitors, or NRTIs, are commonly used to treat HIV.
Scienmag
NOVEMBER 9, 2020
Credit: Insilico Tuesday, November 10, 2020 (9AM Beijing) – Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, today announced that it entered into a multi-target drug discovery agreement with Janssen Pharmaceutica N.V.
Scienmag
SEPTEMBER 4, 2020
Anticholinergic medications are used for many conditions but might also accelerate cognitive decline, especially in older persons with biological or genetic risk factors A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies (..)
Scienmag
DECEMBER 23, 2020
The Phase 3 clinical trial showed that the drug, called CC-486, significantly improved survival in older patients, over the age of 55, with AML A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement […].
Scienmag
MARCH 25, 2021
AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases Credit: Insilico Medicine Thursday, 25th of March 2021 (5:00AM EST) — Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing (..)
Expert insights. Personalized for you.
84 
Let's personalize your content